secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2023-10-31T23:59:59+00:00
Accession:  0001104659-23-112750
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa Q3 ARCALYST revenue $64.8M (+94% YoY); tracking to high end of FY guidance
--------------------------------------------------------------------------------

- ARCALYST net product revenue $64.8M, ~94% YoY growth; total revenue $67.0M (incl. $2.2M license).
- Net loss $13.9M vs net income $224.1M in Q3 2022 (prior year included $65.7M license revenue).
- Cash $201.1M, no debt; expected to fund operations into at least 2027.
- KPL-404 Phase 2 RA data from Cohorts 1-3 expected Q1 2024; Cohort 4 data expected Q2 2024.
- FY2023 ARCALYST revenue guidance $220-230M, tracking to high end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465923112750/0001104659-23-112750-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465923112750/tm2329311-1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-112750

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer